Piper Sandler Maintains MultiPlan(MPLN.US) With Hold Rating, Maintains Target Price $40
Piper Sandler Sticks to Their Hold Rating for MultiPlan (MPLN)
Citi Maintains MultiPlan(MPLN.US) With Hold Rating, Cuts Target Price to $10
MultiPlan Analyst Ratings
Citigroup Maintains Neutral on MultiPlan, Lowers Price Target to $10
MultiPlan Price Target Cut to $1.00/Share From $2.00 by Piper Sandler
MultiPlan Analyst Ratings
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)
MultiPlan Analyst Ratings
Barclays Sticks to Its Hold Rating for MultiPlan (MPLN)
Barclays Adjusts Price Target on MultiPlan to $1 From $3, Maintains Equal-Weight Rating
Goldman Sachs Adjusts Price Target on MultiPlan to $2.05 From $5.50, Maintains Neutral Rating